Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. reports a significant milestone with a patient showing a long-term complete response to their drug namodenoson, exceeding 7 years of survival with advanced liver cancer. The promising results, published in a scientific journal, coincide with ongoing Phase III trials in the US, Europe, and Israel, evaluating namodenoson as a potential treatment for liver cancer, which could meet a critical market need. Namodenoson, with Orphan Drug and Fast Track statuses, demonstrates Can-Fite’s commitment to addressing the challenging hepatocellular carcinoma market estimated to reach $3.8 billion by 2027.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
